Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 300Carcinoma, Non-Small-Cell Lung 80Squamous Cell Carcinoma of Head and Neck 59Carcinoma, Renal Cell 58Neoplasms 40Neoplasm Metastasis 36Colorectal Neoplasms 36Stomach Neoplasms 29Carcinoma, Merkel Cell 29Triple Negative Breast Neoplasms 28Ovarian Neoplasms 28Carcinoma, Transitional Cell 27Uterine Cervical Neoplasms 24Skin Neoplasms 24Head and Neck Neoplasms 24Lung Neoplasms 22Breast Neoplasms 21Carcinoma, Hepatocellular 19Parkinson Disease 4, Autosomal Dominant Lewy Body 18Esophageal Neoplasms 18Pancreatic Neoplasms 16Uveal Melanoma 14Small Cell Lung Carcinoma 14Sarcoma 14Urinary Bladder Neoplasms 12Lymphoma 11Kidney Neoplasms 11Endometrial Neoplasms 11Brain Neoplasms 11Prostatic Neoplasms 10

Interventions

tebentafusp 1pembrolizumab 1Transdermal Patch 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Nevus, Blue × pembrolizumab × Dermatologic × Clear all
NCT05549297 2026-02-25

Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM)

Immunocore Ltd

Phase 3 Recruiting
540 enrolled
Dermatologic

Melanoma, Nevus, Blue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡